Brain tumor drug receives rare disease designations from the FDA

(Oklahoma Medical Research Foundation) The Food and Drug Administration has given Orphan Disease Designation and Rare Pediatric Disease Designation to OKN-007, an experimental brain cancer treatment currently in Phase 2 clinical trials at eight U.S. sites.